Compare Heron Therapeutics Inc (HRTX) vs Banco Santander SA (SAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Banco Santander SA — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.04M), while Banco Santander SA trades at $13.5 (market cap $199.76B). The key difference: Banco Santander SA is far larger — about 2698× Heron Therapeutics Inc's market cap, and Banco Santander SA pays a 2.04% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Banco Santander SA for 55 Days on average.
| HRTX | SAN | |
|---|---|---|
Market Cap | $74.04M | $199.76B |
Volume | 3,668,095 | 10,857,025 |
Sector | Health | Financials |
52-Week High | $1.49 | $15.05 |
52-Week Low | $0.27 | $9.65 |
Typical Hold Time | 35 Days | 55 Days |
Enterprise Value | $180.78M | $358.81B |
Dividend Yield | — | 2.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
Banco Santander (SAN) trades at $13.48, down 3.78% with bearish technical signals despite strong fundamentals. The stock shows mixed earnings performance with Q1 2026 beating estimates but Q2 missing, while maintaining robust profitability with 26.25% net margin and 16.07% ROE. Recent developments include the completed Webster Financial acquisition expanding U.S. presence and record Q2 2026 profits driven by digital transformation.
SAN presents a value opportunity with reasonable P/E of 13.77 and strong analyst support (64% buy ratings), though negative cash flow trends and rising debt-to-asset ratio to 17.8% pose concerns. The stock's current bearish technical positioning near support at $13 may offer entry points for long-term investors betting on the bank's strategic expansion and efficiency gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
